Abstract
We present clinical practice guidelines for the diagnosis and treatment of homozygous familial hypercholesterolaemia (HoFH) in the Middle East region. While guidelines are broadly applicable in Europe, in the Middle East we experience a range of confounding factors that complicate disease management to a point whereby the European guidance cannot be applied without significant modification. Specifically, for disease prevalence, the Middle East region has an established epidemic of diabetes and metabolic syndrome that can complicate treatment and mask a clinical diagnosis of HoFH. We have also a high incidence of consanguineous marriages, which increase the risk of transmission of recessive and homozygous genetic disorders. This risk is further augmented in autosomal dominant disorders such as familial hypercholesterolaemia (FH), in which a range of defective genes can be transmitted, all of which contribute to the phenotypic expression of the disease. In terms of treatment, we do not have access to lipoprotein apheresis on the same scale as in Europe, and there remains a significant reliance on statins, ezetimibe and the older plasma exchange methods. Additionally, we do not have widespread access to anti-apolipoprotein B therapies and microsomal transfer protein inhibitors. In order to adapt existing global guidance documents on HoFH to the Middle East region, we convened a panel of experts from Oman, Saudi Arabia, UAE, Iran and Bahrain to draft a regional guidance document for HoFH. We also included selected experts from outside the region. This panel statement will form the foundation of a detailed appraisal of the current FH management in the Middle Eastern population and thereby provide a suitable set of guidelines tailored for the region.
Keywords: Homozygous familial hypercholesterolaemia, prevalence, diagnosis, treatment, genetics.
Current Vascular Pharmacology
Title:Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel
Volume: 13 Issue: 6
Author(s): Abdullah Al-Ashwal, Fahad Alnouri, Hani Sabbour, Abdulraof Al-Mahfouz, Nasreen Al-Sayed, Maryam Razzaghy-Azar, Faisal Al-Allaf, Khalid Al-Waili, Yajnavalka Banerjee, Jacques Genest, Raul D. Santos and Khalid Al-Rasadi
Affiliation:
Keywords: Homozygous familial hypercholesterolaemia, prevalence, diagnosis, treatment, genetics.
Abstract: We present clinical practice guidelines for the diagnosis and treatment of homozygous familial hypercholesterolaemia (HoFH) in the Middle East region. While guidelines are broadly applicable in Europe, in the Middle East we experience a range of confounding factors that complicate disease management to a point whereby the European guidance cannot be applied without significant modification. Specifically, for disease prevalence, the Middle East region has an established epidemic of diabetes and metabolic syndrome that can complicate treatment and mask a clinical diagnosis of HoFH. We have also a high incidence of consanguineous marriages, which increase the risk of transmission of recessive and homozygous genetic disorders. This risk is further augmented in autosomal dominant disorders such as familial hypercholesterolaemia (FH), in which a range of defective genes can be transmitted, all of which contribute to the phenotypic expression of the disease. In terms of treatment, we do not have access to lipoprotein apheresis on the same scale as in Europe, and there remains a significant reliance on statins, ezetimibe and the older plasma exchange methods. Additionally, we do not have widespread access to anti-apolipoprotein B therapies and microsomal transfer protein inhibitors. In order to adapt existing global guidance documents on HoFH to the Middle East region, we convened a panel of experts from Oman, Saudi Arabia, UAE, Iran and Bahrain to draft a regional guidance document for HoFH. We also included selected experts from outside the region. This panel statement will form the foundation of a detailed appraisal of the current FH management in the Middle Eastern population and thereby provide a suitable set of guidelines tailored for the region.
Export Options
About this article
Cite this article as:
Al-Ashwal Abdullah, Alnouri Fahad, Sabbour Hani, Al-Mahfouz Abdulraof, Al-Sayed Nasreen, Razzaghy-Azar Maryam, Al-Allaf Faisal, Al-Waili Khalid, Banerjee Yajnavalka, Genest Jacques, Santos D. Raul and Al-Rasadi Khalid, Identification and Treatment of Patients with Homozygous Familial Hypercholesterolaemia: Information and Recommendations from a Middle East Advisory Panel, Current Vascular Pharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570161113666150827125040
DOI https://dx.doi.org/10.2174/1570161113666150827125040 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Biotechnology Repair of Dilated Aortic Root and Sinotubular Junction Using a Stabilizer Ring
Recent Patents on Cardiovascular Drug Discovery Gene Delivery Strategies Targeting Stable Atheromatous Plaque
Current Pharmaceutical Design Low Activity of Plasminogen Activator: A Common Feature of Non- Iatrogenic Comorbidities of Schizophrenia
CNS & Neurological Disorders - Drug Targets State-of-the-Art Review of Current Therapies for HFpEF: An Overview of Interatrial Septal Device Therapy in Heart Failure
Current Cardiology Reviews The Role of Matrix Metalloproteinases in Diabetes Mellitus
Current Topics in Medicinal Chemistry Direct Cardiac Reprogramming with Engineered miRNA Scaffolds
Current Pharmaceutical Design Editorial from Guest Editor [Hot Topic Perinatal Stem Cells Revisited: Directions and Indications at the Crossroads Between Tissue Regeneration and Repair]
Current Stem Cell Research & Therapy Antiatherosclerotic and Cardioprotective Effects of Time-Released Garlic Powder Pills
Current Pharmaceutical Design Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews Nanosuspensions as a Versatile Carrier based Drug Delivery System - An Overview
Current Drug Delivery Patent Selections
Recent Patents on Anti-Infective Drug Discovery Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users
Current Pharmaceutical Design Sex-Gender Differences in Diabetes Vascular Complications and Treatment
Endocrine, Metabolic & Immune Disorders - Drug Targets The Cardiovascular Protective Effects of Chrysin: A Narrative Review on Experimental Researches
Cardiovascular & Hematological Agents in Medicinal Chemistry Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Cellular Protection and Therapeutic Potential of Tocotrienols
Current Pharmaceutical Design The Secondary Heart Field: Understanding Conotruncal Defects from a Developmental Perspective
Current Cardiology Reviews Inflamm-ageing and senescence in gout: the tale of an old king’s disease.
Current Aging Science Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets